Literature DB >> 8430949

The role of endothelium in hypoxic constriction of human pulmonary artery rings.

A T Demiryurek1, R M Wadsworth, K A Kane, A J Peacock.   

Abstract

The aim of the study was to elucidate the mechanism of the contraction produced by hypoxia in human intrapulmonary artery rings. Hypoxia (5 mm Hg) produced a contraction that was greater when the artery rings were precontracted (with endothelin-1) than when recorded under optimal resting force. The contraction was similar in small-diameter (0.38 to 0.68 mm) and in large-diameter (2.2 to 4.5 mm) artery rings under resting force. Removal of the endothelium markedly reduced or abolished the hypoxic contraction in precontracted artery rings (large diameter, 26 +/- 9 to -7 +/- 4 g cm-2) or under optimal resting force. Hypoxia markedly reduced or abolished the acetylcholine-induced relaxation in precontracted artery rings without affecting relaxation produced by sodium nitroprusside. Flurbiprofen caused a slight contraction itself (large diameter, 10 +/- 3 g cm-2) and significantly inhibited the contraction produced by hypoxia both under resting force (8 +/- 2 to 2 +/- 1 g cm-2) and in precontracted artery rings (18 +/- 2 to 1 +/- 1 g cm-2). Verapamil had no significant effect on the hypoxic contraction either under resting force or when precontracted. It is concluded that hypoxic contraction of human pulmonary artery rings depends on the presence of endothelium and is partly due to inhibition of a vasodilator cyclooxygenase product.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8430949     DOI: 10.1164/ajrccm/147.2.283

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  18 in total

Review 1.  Role of serotonin in the pathogenesis of acute and chronic pulmonary hypertension.

Authors:  P Egermayer; G I Town; A J Peacock
Journal:  Thorax       Date:  1999-02       Impact factor: 9.139

2.  Mobilization of sarcoplasmic reticulum stores by hypoxia leads to consequent activation of capacitative Ca2+ entry in isolated canine pulmonary arterial smooth muscle cells.

Authors:  Lih Chyuan Ng; Sean M Wilson; Joseph R Hume
Journal:  J Physiol       Date:  2004-12-21       Impact factor: 5.182

Review 3.  Endothelial modification of pulmonary vascular tone.

Authors:  N P Curzen; K B Jourdan; J A Mitchell
Journal:  Intensive Care Med       Date:  1996-06       Impact factor: 17.440

Review 4.  Pulmonary hypertension in obstructive sleep apnea: is it clinically significant? A critical analysis of the association and pathophysiology.

Authors:  Cyrus Kholdani; Wassim H Fares; Vahid Mohsenin
Journal:  Pulm Circ       Date:  2015-06       Impact factor: 3.017

5.  Voltage-independent calcium entry in hypoxic pulmonary vasoconstriction of intrapulmonary arteries of the rat.

Authors:  T P Robertson; D Hague; P I Aaronson; J P Ward
Journal:  J Physiol       Date:  2000-06-15       Impact factor: 5.182

Review 6.  Hypoxic pulmonary vasoconstriction: mechanisms and controversies.

Authors:  Philip I Aaronson; Tom P Robertson; Gregory A Knock; Silke Becker; Tristan H Lewis; Vladimir Snetkov; Jeremy P T Ward
Journal:  J Physiol       Date:  2005-10-27       Impact factor: 5.182

7.  Vasodilators in pulmonary hypertension.

Authors:  A Peacock
Journal:  Thorax       Date:  1993-12       Impact factor: 9.139

8.  Divergent roles of glycolysis and the mitochondrial electron transport chain in hypoxic pulmonary vasoconstriction of the rat: identity of the hypoxic sensor.

Authors:  R M Leach; H M Hill; V A Snetkov; T P Robertson; J P Ward
Journal:  J Physiol       Date:  2001-10-01       Impact factor: 5.182

Review 9.  Human pulmonary vascular responses to hypoxia and hypercapnia.

Authors:  K L Dorrington; N P Talbot
Journal:  Pflugers Arch       Date:  2004-10       Impact factor: 3.657

Review 10.  ROS-dependent signaling mechanisms for hypoxic Ca(2+) responses in pulmonary artery myocytes.

Authors:  Yong-Xiao Wang; Yun-Min Zheng
Journal:  Antioxid Redox Signal       Date:  2010-03-01       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.